Results 131 to 140 of about 1,287,782 (264)

Mapping convergent regulators of melanoma drug resistance by PerturbFate. [PDF]

Nature
Xu Z, Lu Z, Ugurbil A, Abdulraouf A, Liao A, Zhang J, Zhou W, Cao J.   +7 more
europepmc   +1 more source

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. [PDF]

Cell Rep
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y, Wang J, Gadaleta E, Chelala C, Moore KM, Marshall JF, Chupin J, Schmid P, Jones JL, Lockley M, Cutillas PR, Grose RP.   +18 more
europepmc   +1 more source

Derivation and characterization of retinal pigment epithelium from urine‐derived iPSCs

FEBS Open Bio, EarlyView.
Age‐related macular degeneration causes vision loss via RPE dysfunction and loss. Traditional iPSC therapies rely on invasive biopsies, limiting scalability. Here, we utilize urine‐derived stem cells as an accessible source to generate u‐iPSCs, successfully differentiated into pigmented RPE. This “Urine‐to‐Retina” platform provides a promising path for
Daniella Beiner, Hainan Zhu, Carol Christine Bosholm, Heuy‐Ching Wang, Tracy Criswell, Anthony Atala, Jian‐Xing Ma, Yuanyuan Zhang   +7 more
wiley   +1 more source

Identification of Specific LncRNA Markers in Severe Tuberculosis for Early Diagnosis

Infection and Drug Resistance
Siyu Yao,1,* Xiuxiu Ji,2,* Ruize Wang,1 Liping Pan,2 Qiuyue Liu1 1Department of Critical Care Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, People’s ...
Yao S, Ji X, Wang R, Pan L, Liu Q
doaj  

Challenges and advances in drug resistance and tolerance in cancer. [PDF]

J Exp Clin Cancer Res
Bivona TG, Yanai I, Calabrò F, Mechta-Grigoriou F, Corleone G, Di Martile M, Tocci A, Tocci P, Vaccarella S, Ferriero MC, Alimonti A, Ruppin E, Nisticò P, Bagnato A, Blandino G.   +14 more
europepmc   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Distribution and Drug-Resistance Analysis of Uropathogens in Urinary Tract Infections. [PDF]

Can J Infect Dis Med Microbiol
Wu W, Wu Q, Zhong W, Han L.
europepmc   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

Targeting metabolism to combat anticancer and antibacterial drug resistance. [PDF]

Trends Pharmacol Sci
Chung CH, Bhowmick R, Badenoch AJ, Arora HS, Chandrasekaran S.   +4 more
europepmc   +1 more source